A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: One stone for two birds?

British Journal of Clinical Pharmacology

Volumn 81, Issue 2, 2016, Pages 341-348

  Pea, Federico ^a,b   Cojutti, Piergiorgio ^a,b   Dose, Lucia ^a   Baraldo, Massimo ^a,b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

clinical pharmacological advice; cost balance analysis; linezolid; therapeutic drug monitoring

Indexed keywords

LINEZOLID; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BONE AND JOINT INFECTIONS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL EFFECTIVENESS; CLINICAL PHARMACOLOGY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG MONITORING; ENDOCARDITIS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HYPERLACTATEMIA; MAJOR CLINICAL STUDY; MEDICAL AUDIT; MINIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NEUROTOXICITY; NOCARDIOSIS; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; SKIN INFECTION; SOFT TISSUE INFECTION; TERTIARY CARE CENTER; THROMBOCYTOPENIA; BLOOD; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DOSE RESPONSE; ECONOMICS; HEALTH CARE QUALITY; MEDICATION COMPLIANCE; PRESCRIPTION; PROCEDURES;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; DRUG MONITORING; DRUG PRESCRIPTIONS; HUMANS; LINEZOLID; MEDICATION ADHERENCE; PHARMACOLOGY, CLINICAL; PRECISION MEDICINE; QUALITY INDICATORS, HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 84963615220     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12806     Document Type: Article

References (33)

1. Birkett D, Brosen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, Rawlins M, Reidenberg M, Sjoqvist F, Smith T, Thuerman P, Walubo A, Orme M, Sjoqvist F,. Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 2010; 107: 531-59.
2. Eliasson E, Lindh JD, Malmstrom RE, Beck O, Dahl ML,. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol 2013; 69: 25-32.
3. Pea F, Dose L, Cojutti P, Baraldo M, Fontana F, Favaretti C, Furlanut M,. Educational and organizational interventions to improve the usefulness of clinical pharmacological advice for personalized drug dosing based on therapeutic drug monitoring. Basic Clin Pharmacol Toxicol 2014; 115: 432-7.
4. Watson IP, Yatscoff JR,. Therapeutic drug monitoring. Ther Drug Monit 1997; 19: 125.
5. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL, International Society of Anti-Infective Pharmacology, the Pharmacology and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
6. Roberts JA, Hope WW, Lipman J,. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents 2010; 35: 419-20.
7. Zoller M, Maier B, Hornuss C, Neugebauer C, Dobbeler G, Nagel D, Holdt LM, Bruegel M, Weig T, Grabein B, Frey L, Teupser D, Vogeser M, Zander J,. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care 2014; 18: R148.
8. Dong H, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H,. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2011; 38: 296-300.
9. Woodford N, Livermore DM,. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009; 59: S4-16.
10. Caminero JA, Sotgiu G, Zumla A, Migliori GB,. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-9.
11. Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher ES, Birmingham MC, Schentag JJ, Gimbel JF, Apodaca A, Schwartz MA, Rakita RM, Wallace RJ Jr,. Clinical experience with linezolid for the treatment of nocardia infection. Clin Infect Dis 2003; 36: 313-8.
12. Papadopoulos A, Plachouras D, Giannitsioti E, Poulakou G, Giamarellou H, Kanellakopoulou K,. Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study. J Chemother 2009; 21: 165-9.
13. Cojutti P, Maximova N, Crichiutti G, Isola M, Pea F,. Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother 2015; 70: 198-206.
14. Pea F, Cadeo B, Cojutti PG, Pecori D, Bassetti M,. Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: a case report. Ther Drug Monit 2014; 36: 687-9.
15. Pea F, Scudeller L, Lugano M, Baccarani U, Pavan F, Tavio M, Furlanut M, Rocca GD, Bresadola F, Viale P,. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 2006; 42: 434-5.
16. Richards GA, Brink AJ,. Therapeutic drug monitoring: linezolid too? Crit Care 2014; 18: 525.
17. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, Morita K, Kamimura H, Karube Y,. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 2011; 17: 70-5.
18. Hiraki Y, Tsuji Y, Hiraike M, Misumi N, Matsumoto K, Morita K, Kamimura H, Karube Y,. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis 2012; 44: 60-4.
19. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M,. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012; 67: 2034-42.
20. Touw DJ, Neef C, Thomson AH, Vinks AA, Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Therapeutics. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 2005; 27: 10-7.
21. Streetman DS, Nafziger AN, Destache CJ, Bertino AS Jr,. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy 2001; 21: 443-51.
22. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA,. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999; 21: 63-73.
23. Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE,. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 2003; 23: 643-50.
24. Fernandez de Gatta MD, Calvo MV, Hernandez JM, Caballero D, San Miguel JF, Dominguez-Gil A,. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996; 60: 332-40.
25. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P,. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010; 54: 4605-10.
26. Pea F, Viale P, Lugano M, Pavan F, Scudeller L, Della Rocca G, Furlanut M,. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis 2004; 44: 1097-102.
27. Roberts JA, Norris R, Paterson DL, Martin JH,. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012; 73: 27-36.
28. Andes D, Pascual A, Marchetti O,. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
29. Alsultan A, Peloquin CA,. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-54.
30. Pea F, Lugano M, Baccarani U, Della Rocca G, Viale P,. Biliary pharmacodynamic exposure to linezolid in two liver transplant patients. J Antimicrob Chemother 2014; 69: 567-8.
31. Pea F, Viale P,. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006; 42: 1764-71.
32. Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, Yata N, Yotsuyanagi H, Moriya K,. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 2013; 68: 2128-33.
33. Pea F, Cojutti P, Pagotto A, Cristini F, Furlanut M, Viale P,. Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. Antimicrob Agents Chemother 2012; 56: 3438-40.